Angiogenesis plays an important role in tumor growth and metastasis and has been reported to be inversely correlated with overall survival of osteosarcoma patients. It has been shown that apurinic ⁄ apyrimidinic endonuclease 1 (APE1), a dually functional protein possessing both base excision repair and redox activities, is involved in tumor angiogenesis, although these mechanisms are not fully understood. Our previous study showed that the expression of transforming growth factor b (TGFb) was significantly reduced in APE1-deficient osteosarcoma cells. Transforming growth factor b promotes cancer metastasis through various mechanisms including immunosuppression, angiogenesis, and invasion. In the current study, we initially revealed that APE1, TGFb, and microvessel density (MVD) have pairwise correlation in osteosarcoma tissue samples, whereas TGFb, tumor size, and MVD were inversely related to the prognosis of the cohort. We found that knocking down APE1 in osteosarcoma cells resulted in TGFb downregulation. In addition, APE1-siRNA led to suppression of angiogenesis in vitro based on HUVECs in Transwell and Matrigel tube formation assays. Reduced secretory protein level of TGFb of culture medium also resulted in decreased phosphorylation of Smad3 of HUVECs. In a mouse xenograft model, siRNA-mediated silencing of APE1 downregulated TGFb expression, tumor size, and MVD. Collectively, the current evidence indicates that APE1 regulates angiogenesis in osteosarcoma by controlling the TGFb pathway, suggesting a novel target for anti-angiogenesis therapy in human osteosarcoma.
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O steosarcoma is a bone malignancy frequently diagnosed among children and adolescents.
(1) Therapeutic approaches for osteosarcoma patients combine neoadjuvant chemotherapy and limb-sparing operations. (2) Although adjuvant and neoadjuvant chemotherapy have significantly improved the long-term survival rate for patients, approximately 30-40% have recurrent disease and approximately 80% develop metastasis following surgery, so that recurrence and metastatic relapse remain problematic. (3) (4) (5) Furthermore, the 5-year survival rate for patients with metastasis or relapsed osteosarcoma has remained at approximately 20% for decades. (6) Therefore, to facilitate the therapeutic effect and inhibit metastasis, the exploration of novel prognostic factors is of great importance in the development of new treatment strategies for osteosarcoma patients.
Osteosarcoma is a highly vascularized tumor characterized by an early metastatic dissemination potential, which is the main reason for treatment failure and death, and minimal vascularization at the time of diagnosis predicts good response to neoadjuvant chemotherapy, along with a prolonged overall and relapse-free survival. (7) (8) (9) Thus, targeting angiogenesis is a promising therapeutic approach to osteosarcoma treatment. It is widely accepted that tumor growth and metastasis need vascular support and tumor-associated angiogenesis is a multistep process orchestrated by positive and negative regulatory factors; therefore, the imbalance of angiogenic regulators, such as vascular endothelial growth factor (VEGF) and angiopoietins, may be the cause of the abnormal structure and function of tumor vessels. (10, 11) Human apurinic ⁄ apyrimidinic endonuclease 1 (APE1) is a multifunctional protein involved in redox regulation of transcription factors and the DNA base excision pathway, in which the oxidative base damage is caused by both endogenous and exogenous agents. (12, 13) In particular, its redox activity is now considered to participate in multiple cancer survival mechanisms such as tumor growth, proliferation, and metastasis, and it plays a key role in pathological angiogenesis by regulating various transcription factors. (14, 15) Our previous study reported that APE1 expression correlates with poor prognosis of osteosarcoma. (16) In subsequent studies, when knocking down APE1, a synergistic growth attenuation together with angiogenic inhibition was observed with recombinant human endostatin in osteosarcoma cell xenografts in null mice, suggesting APE1 involvement in osteosarcoma angiogenesis. (17) To explain this phenomenon, we found both VEGF and fibroblast growth factor 2 (FGF2) are regulated by APE1 redox activity through transcription factors, hypoxia-inducible factor-1a (HIF-1a), and signal transducer and activator of transcription 3, separately. (17, 18) Interestingly, we observed an additional inhibition of angiogenesis by knocking down APE1, even when supplemented with exogenous VEGF and FGF2, implying there might be other APE1-regulated mechanisms involved in tumor angiogenesis.
Transforming growth factor b (TGFb) constitutes a family of multifunctional peptides that take part in diverse processes of cellular biology, as well as metastasis. (19, 20) Additionally, TGFb participates in tumor angiogenesis in cooperation with other angiogenic activators and inhibitors. Transforming growth factor b stimulates angiogenesis through its effects on tumor cells and angiogenic cytokine networks that induce a pro-angiogenic environment, so that increased TGFb expression results in robust angiogenic responses that further promote tumor metastasis. (21) Franchi et al. reported a higher mRNA level of TGFb1 in high-grade osteosarcoma than in lowergrade, suggesting that TGFb1 may predict aggressive behavior of osteosarcoma. (22) It was also reported that APE1 was correlated with poor prognosis of osteosarcoma. Based on our previous observations, (23) we thereby hypothesized that TGFb could contribute to the regulatory role of APE1 in osteosarcoma angiogenesis.
This study aims to investigate the interaction between APE1 and TGFb in the angiogenesis of osteosarcoma. First, our data showed that high expression of APE1, TGFb, and microvessel density (MVD) correlate with poor prognosis of osteosarcoma patients, with a pairwise correlation between each. Second, TGFb, tumor size, and MVD were important indicators and inversely related to prognosis. According to the above analysis, we speculated that APE1 may indirectly regulate angiogenesis through a TGFb-dependent pathway and carried out in vivo and in vitro assays to confirm this. This is the first study of the role of APE1 regulating TGFb in tumor angiogenesis in osteosarcoma.
Materials and Methods
Clinical cases. Eighty patients with long bone intramedullary osteosarcoma in the extremities were treated in Daping Hospital (Chongqing, China) between 1968 and 1993. There were 52 male and 28 female patients, who provided signed, informed consent. Among these patients, 75 had surgery and 5 had biopsy; 54 (67.50%) were in their twenties, and 74 (92.50%) had a tumor size of 5-25 cm in diameter with soft tissue invasion. The bone tumor types and histological grades were determined based on the Enneking staging system (24) and Ross FG classification. (25) Thirty-five patients had the affected limb amputated with subsequent chemotherapy, 24 had amputation only, 17 had abscission of the tumoral segment followed by end-to-end connection of the amputated ends or inactivation and replantation, and 4 patients did not receive any treatment.
Immunohistochemical analysis. Tumor tissues were fixed in 4% paraformaldehyde at room temperature overnight, then dehydrated and embedded in paraffin, followed by sectioning (RM2235; Leica, Solms, Germany) of the tumor tissue at 4.5 lm per slide. After applied with the primary antibodies, 3,3 0 -diaminobenzidine was used as a chromogenic substrate and hematoxylin for counterstaining. The intensity of immunohistochemical (IHC) staining was graded from 0 to 3 as reported in Khoury et al. (26) The tissue showed less than 25% positive cells was defined as low staining intensity, 25-50% positive cells was moderate staining intensity, and more than 50% positive cells was high staining intensity. All CD34-positive endothelial cells separated from adjacent microvessels were defined as MVD. The eyepiece graticule was rotated to view the maximum number of stained vessels under 2009 magnification for the quantification of MVD. Three fields were captured for each section and the expression of the results was the mean AE SD. Primary antibody was the substitution for PBS as a negative control. RNA was extracted and reverse-transcripted to cDNA using the RevertAid First-Strand cDNA Synthesis Kit (Thermo Scientific, Massachusetts, USA) for RT-PCR following the manufacturer's instructions. Reverse transcription-PCR for TGFb was carried out as previously described, (27) and the following cycle profile was used for both APE1 and b-actin: 94°C for 2 min, 40 cycles of denaturation at 94°C for 45 s, annealing at 58°C for 30 s, and extension at 72°C for 20 s.
Enzyme-linked immunosorbent assay, Transwell migration, Matrigel tube formation assay, and Western blot analysis. The supernatant from 9901 cells were measured using a TGF-b1 ELISA kit (Invitrogen). The absorbance of each well was read at 450 nm. The Transwell migration assay was carried out in a 24-well plate with an 8.0-lm pore Transwell chamber (BD Biosciences, San Diego, CA, USA). The serum-free DMEM medium containing 18 000 HUVECs was inoculated into the upper chamber. The lower compartments were filled with the supernatant from culturing 9901 cells with Opti-MEM I medium, 0.2 nM APE1-siRNA, and 0.2 nM APE-1-siRNA supplemented with purified TGFb protein at the concentration of 2 or 5 ng ⁄ mL. After incubation for 20 h, the migrated cells were fixed with formaldehyde and stained with crystal violet, followed by counting from four random zones by light microscopy at 2009 magnification. For the Matrigel tube formation assay, supernatant as indicated above was mixed with 20 lL DMEM containing 2 9 10 4 HUVECs then transferred to the 24-well plate on the Matrigel matrix separately, followed by incubation at 37°C, 5% CO 2 , for 12 h.
Three groups of HUVECs were tested for protein levels of Smad3 and phosphorylated Smad3. The culture medium of these groups were supernatants of untreated 9901 cells, 9901 cells treated with 0.2 nM APE1-siRNA, or 9901 cells treated with 0.2 nM APE1-siRNA plus purified recombinant TGFb protein (2 ng ⁄ mL; PeproTech, Rocky Hill, NJ, USA). After 2 h of conditioning culture, three groups of HUVECs were tested for protein levels of pan and phosphorylated Smad3 by Western blot. The anti-Smad3 and anti-Smad3 (phospho) antibodies were purchased from Abcam (Cambridge, MA, USA).
Tumor angiogenesis in osteosarcoma xenograft mouse model and IHC analysis. The xenograft model and treatment were carried out as previously described by Wang et al. (17) Balb ⁄ c nude mice were acclimated to autoclaved cages for 1 week and housed with access to food and water ad libitum in HEPA-filtered racks (Dwyer Instruments, Michigan, IN, USA) with close supervision. All experimental protocols were consented to by the Ethics Committee of the Third Military Medical University (Chongqing, China). The 4-5-week-old mice were allocated randomly to each group (n = 5 per group) followed by inoculation with a suspension of 9901 cells in the axilla of the right anterior limbs. Injection of 20 lg APE1-siRNA into these mice was carried out once every 3 days for 14 consecutive days and mice in the control group received the same volume of PBS when the size of the tumor was approximately 50 mm 3 . Mice were killed on the 14th day, and the tumors were excised and fixed in formalin solution for IHC analysis. The gross tumor volume was calculated according to the formula D max (maximum diameters) 9 D min (minimum diameters) 2 9 0.52. (28) The results were the sum of the integral optical density and quantified by Image-Pro Plus analysis software (Media Cybernetics, Inc., Rockville, MD, USA).
Statistical analysis. The data were calculated from triplicate experiments and quantitative data were represented as the mean AE SD. Student's t-test or the Kruskal-Wallis test was used for measurement data; the v 2 -test or Fisher's exact probability were used for count data. The Kaplan-Meier survival test was used to compare the overall survival rate between TGFb-positive and TGFb-negative groups. Spearman's rank correlation coefficient was used to evaluate the association between MVD, APE1, and TGFb expression in osteosarcoma patients. The measurement data are presented as the mean AE SD. A P-value < 0.05 was regarded as having statistical significance.
Results
Expression of APE1, TGFb, and CD34 in human osteosarcoma. To investigate the potential correlation between APE1, TGFb1, and CD34 in osteosarcoma patients, 80 osteosarcoma tissues were immunohistochemically stained. Representative IHC staining with high and low expression of APE1, TGFb1, and CD34 in osteosarcoma patients are shown in Figure 1 . APE1 staining was generally localized in both the nucleus and cytoplasm, and 55 cases showed high APE1 expression levels (68.75%). The TGFb1 staining was mainly localized in the cytoplasm with high expression observed in 31 cases (38.75%). CD34 staining was mostly localized in the membrane and cytoplasm of vascular endothelial cells in the tumor stroma, and was positive on endothelial cells representing the microvessel. Thirty-four cases had MVD surpassing 37.62 (42.50%). Due to the high expression of APE1 and TGFb, which was postulated to be correlated with high MVD, the investigation was carried out in osteosarcoma tissues. The expression of these three proteins was positively correlated to each other and the results are presented in Table 1 . The Cox hazard probability regression model was used to evaluate the potential prognostic factors. As shown in Figure 2 , the 2-and 5-year survival rates of osteosarcoma patients were 33.8% and 18.3%, respectively. The baseline patient characteristics (Table 2) were similar to a previous report from our group. The data revealed that TGFb, MVD, and tumor size were important prognostic factors for osteosarcoma. APE1 was excluded in the final model, suggesting its prognostic effect may be dependent on other factors. According to the hazard ratio, the rank of effectiveness of these prognostic factors was TGFb > tumor size > MVD (Table 3) .
Apurinic ⁄ apyrimidinic endonuclease 1-siRNA-mediated downregulation in osteosarcoma cells inhibits expression of TGFb1.
We then tested whether TGFb1 expression is affected by APE1 exogenous manipulation in 9901 cells by Western blot. As shown in Figure 3 , the expression of APE1 was decreased in APE1-siRNA transfected cells when compared with the scramble-siRNA transfected cells and blank control. When APE1 was knocked down, TGFb1 expression was downregulated. The percentage inhibition of APE1 and TGFb1 protein was 88.75% and 63.1% compared to the blank control, respectively (P < 0.01), and there were no differences between the scramble and blank control. To evaluate the secretory level of TGFb1 affected by APE1 deficiency, an ELISA was carried out. The results indicated that knocking down APE1 in 9901 cells results in a significant decrease in TGFb1 levels in the supernatant when compared with control groups (435.23 AE 22.80 pg ⁄ mL for the APE1-siRNA group, 731.610 AE 48.949 pg ⁄ mL for the blank control group, and 755.75 AE 51.36 pg ⁄ mL for the scramble group with an inhibition level of 40.51% (Fig. 3d ). To investigate the mRNA level of TGFb1 expression after knocking down APE1-siRNA, we carried out an RT-PCR assay (P < 0.01; Fig. 4a ). In APE1-siRNA transfected 9901 cells, the expression of APE1 was decreased by 50.81% (P < 0.01; Fig. 4b ). As a result of APE1 knockdown, TGFb1 expression was downregulated by 49.54% (P < 0.01; Fig. 4c) . The above experiments confirmed that exogenous manipulation of APE1 results in altered expression of TGFb1, suggesting a regulatory role of APE1 in TGFb1 signaling.
Apurinic ⁄ apyrimidinic endonuclease 1-siRNA inhibits the capability to enhance HUVEC migration and tube formation of tumor cells through the TGFb ⁄ Smad3 signaling pathway. To test the hypothesis that APE1 regulates tumor angiogenesis through a TGFb-dependent pathway, supplementation with purified TGFb protein in APE1 deficient cells was used to measure the in vitro angiogenic capacity in HUVECs using a Transwell migration and tube formation assay. As shown in Figure 5(a,  b) , fewer HUVECs migrated in the APE1-siRNA transfected group than in the negative control, with a reduction level of 62.6% (P < 0.01). When supplemented with TGFb, the HUVEC migration was restored in a dose-dependent manner. The differences between the two groups were significant (P < 0.01, respectively). Additionally, the Matrigel tube formation assay revealed that fewer capillary-like structures were formed in the APE1-siRNA transfected group than the negative control (P < 0.01), and that TGFb supplementation significantly restored the architecture of tube formation (Fig. 5c,d ). These results suggested that APE1 regulates TGFb during tumor angiogenesis in a dose-dependent manner.
Furthermore, we tested whether the downstream TGFb signaling pathway was affected by APE1 deficiency by measuring the activation of Smad3. As Figure 6 revealed, the pSmad3 level was remarkably decreased to 62.61% in the group treated with supernatant from culturing 9901 cells treated with 0.2 nM APE1-siRNA compared with those without APE1-siRNA (P < 0.01) (Fig. 6c) , while Smad3 levels remained unchanged (Fig. 6b) . Moreover, addition of purified TGFb protein restored the phosphorylated Smad3 level caused by APE1-siRNA (P < 0.01). Taken together, the results indicated that APE1 regulates angiogenesis through the TGFb ⁄ Smad3 signaling pathway.
Tumor angiogenesis and growth in xenografts suppressed by APE1-siRNA. The 9901 cell xenograft model was used to confirm that APE1-siRNA suppresses tumor angiogenesis and growth in vivo. The xenograft model and treatment was the same as in Ren et al., (18) in which the APE1-siRNA treated group resulted in a smaller volume of neoplasm than the PBS treated group (P < 0.01). Tumor sections were analyzed after IHC staining for APE1, TGFb, and CD34. Figure 7 shows representative images of the treatment and control groups. As expected, expression of APE1, TGFb, and MVD was significantly lower in the treatment group compared with the control group (P = 0.033 for APE1; P = 0.041 for TGFb; P = 0.041 for MVD). The data further confirmed the role of APE1 in the angiogenesis of osteosarcoma and suggested it is possibly mediated by TGFb signaling.
Discussion
In this study, we have shown that APE1 and TGFb expression is significantly correlated with poor prognosis in osteosarcoma patients, based on the analysis of clinical data. Subsequently, we confirm that knocking down APE1 in osteosarcoma cells resulted in downregulation of TGFb at both protein and mRNA levels. Angiogenesis is suppressed by APE1-siRNA through the TGFb ⁄ Smad3 signaling pathway in osteosarcoma; addition of TGFb protein restored the reduced pSmad3 and the angiogenic capability of HUVECs induced by APE1 deficiency. Taken together, our results show that APE1 regulates angiogenesis in a TGFb-dependent way in osteosarcoma. Apurinic ⁄ apyrimidinic endonuclease 1 is a multifunctional protein playing crucial roles in DNA base excision repair and redox regulation of gene expression, activities that are functionally and structurally independent of each other. The APE1 redox activity stimulates numerous transcriptional factors, including activator protein-1 (AP-1), nuclear factor-jB (NF-jB), and HIF-1. (14, 29) These factors are involved in mediating VEGF gene expression; HIF-1 and NF-jB, in particular, increased VEGF expression in response to hypoxia. (30) It has been reported that APE1 is an upstream regulator of VEGF in angiogenesis. (14) Our previous study showed that APE1 induced angiogenesis in human osteosarcoma cells by upregulating FGF2 and its receptor 3. (18) However, a previous study by us revealed that exogenous addition of VEGF and FGF2 failed to restore angiogenesis after inhibition by APE1-siRNA. Thus, we infer that APE1 regulated other factors involved in tumor angiogenesis in addition to VEGF and FGF2. Our previous investigation indicated that knockdown of APE1 resulted in the downregulation of factors involved in angiogenesis, such as epidermal growth factor receptor, FGF2, TGFb, TGFb receptor1, and thrombospondin-1 in osteosarcoma cells. (23) Transforming growth factor b has a conserved signaling pathway and its dysregulation in a tumor microenvironment, invasive properties, and immune cell functions could cause cancer metastasis. It can stimulate the generation of myofibroblasts, which produce certain factors and regulate key angiogenic mediators to promote angiogenesis. (20, 21) In particular, TGFb is closely related with the pathogenesis of osteosarcoma and it has been reported by Cao et al. (31) and Zhang et al. (32) that higher serum levels of TGFb were observed in patients with osteosarcoma than in healthy people, although there was no statistical significance between the two groups. However, a significantly higher expression of TGFb was measured in the serum of osteosarcoma patients with metastasis compared to those without metastasis. (23) In this study, we revealed that APE1-siRNA suppresses the capacity of Transwell and tube formation of HUVECs through the TGFb ⁄ Smad3 signaling pathway in osteosarcoma.
Angiogenesis plays a key role in tumor growth and progression, which is considered an indicator of a higher incidence of metastasis and poor prognosis. (10, 33, 34) Moreover, angiogenesis is regulated by both angiogenic stimulators, including members of FGF and VEGF families, as well as angiogenic inhibitors like angiostatin and endostatin. (34) In tumor metastasis, TGFb stimulates angiogenesis by inducing a pro-angiogenic environment and also promotes epithelial-mesenchymal transition (EMT) as a major inducer of both Smad-dependent and Smadindependent signaling pathways. (21) During the process of EMT, epithelial cells lose their polarity, disassemble the cell junction, increase cell motility, and acquire invasive properties to become mesenchymal cells. (21, 35) However, in the case of osteosarcoma, which is a mesenchymal-derived malignant bone tumor, EMT is no longer the key issue, which implies that the overexpressed TGFb might be involved in some pathological process other than EMT. In the aspect of angiogenesis, TGFb1 signaling machinery exerts a protumorigenic effect in canine osteosarcoma. (36) Therefore, we speculate that TGFb promotes tumor progression and metastasis through angiogenesis in osteosarcoma. Sanchez-Elsner et al. discovered that TGFb and the hypoxia signaling pathway synergize in the induction of VEGF gene expression, which stimulates angiogenesis. (37) In primary breast cancer, multiple angiogenic factors, including VEGF, TGFb, and FGF are expressed, (38) and it has been confirmed that TGFb-induced angiogenesis depending on Smad3 promotes bone metastasis in breast cancer. (39) Moreover, TGFb promotes tumor progression probably by stimulating angiogenesis in prostate cancer. (40) It has been confirmed that Smad3, a critical intracellular signaling molecule, has a pro-angiogenic role in response to TGFb1. (41) However, the specific effect APE1 has in these processes is yet to be determined.
It has been confirmed that AP-1 is the main transcription factor that plays a significant role in inducing the second promoter-derived transcription of the TGFb1 gene (sequences between nucleotides +1 and +271), and a family member of AP-1 (Fos-related antigen 2 ⁄ FOSL2) regulates TGFb by interacting with Smad3 in NSCLC. (42, 43) There was also a report that when NF-jB interacted with CCAAT/Enhancer Binding Protein b (C ⁄ EBPb), the activation of TGFb induced by C ⁄ EBPb can be modulated. (44) Moreover, there is evidence that NF-jB activity is involved in AP-1 activation and regulated TGFb expression in angiogenesis. (45, 46) In accordance with previous studies, we propose that APE1, as a redox effector, regulates TGFb, possibly by an AP-1 and NF-jB transcriptional signaling pathway in the angiogenesis of osteosarcoma.
As an additive to our previous studies on the role of APE1 in tumor angiogenesis, our current observations further confirmed TGFb as an important factor controlled by APE1 in contributing to the process of angiogenesis. We believe that our current study, together with previous ones, provides solid evidence that APE1 is a key regulator of tumor angiogenesis through more complicated mechanisms than we initially expected. 
